[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100652805":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":20,"locations":20,"responsibleParty":21,"collaborators":20,"id":25,"slug":26,"hasResults":27,"nctId":28,"briefTitle":29,"officialTitle":30,"acronym":31,"eligibilityCriteria":32,"healthyVolunteers":27,"sex":33,"minAge":34,"maxAge":35,"enrollmentInfo":36,"targetDuration":20,"studyType":39,"phases":40,"briefSummary":42,"conditions":43,"keywords":45,"overallStatus":49,"whyStopped":20,"lastUpdateSubmitDate":50,"lastUpdatePostDateStruct":51,"startDateStruct":54,"completionDateStruct":56,"leadSponsor":58,"locationsCount":20},{"fullName":5,"class":6},"Shanghai Chest Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"septum-guided segmentectomy","EXPERIMENTAL","Participants with 2-3 cm clinical stage IA3 peripheral non-small cell lung cancer and consolidation-to-tumor ratio (CTR) \\>0.5 to \\\u003C=1.0 will undergo planned septum-guided anatomical segmentectomy or combined segmentectomy after intraoperative frozen-section confirmation of node-negative (N0) lymph node status.",[13],"Procedure: septum-guided anatomical segmentectomy",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"PROCEDURE","septum-guided anatomical segmentectomy","septum-guided anatomical segmentectomy or combined segmentectomy performed for eligible peripheral clinical stage IA3 non-small cell lung cancer. The intersegmental vein and intersegmental septal membrane are used as anatomical landmarks to define the intersegmental plane. Intraoperative lymph node frozen-section biopsy must confirm node-negative (N0) status before segmentectomy proceeds; positive nodal disease leads to lobectomy plus systematic lymph node dissection as standard treatment.",[9],null,{"type":22,"investigatorFullName":23,"investigatorTitle":24,"investigatorAffiliation":5,"oldNameTitle":20,"oldOrganization":20},"PRINCIPAL_INVESTIGATOR","Junfeng Geng","Professor","100652805","septum-guided-segmentectomy-for-2-3-cm-clinical-stage-ia3-peripheral-non-small-cell-lung-cancer-100652805",false,"NCT07780591","Septum-guided Segmentectomy for 2-3 cm Clinical Stage IA3 Peripheral Non-Small Cell Lung Cancer","Efficacy and Safety of Septum-guided Segmentectomy for 2-3 cm Clinical Stage IA3 Peripheral Non-Small Cell Lung Cancer: A Single-Center, Prospective, Single-Arm Clinical Trial","SGS2606","Inclusion Criteria:\n\n* Age 18 to 80 years, male or female.\n* Clinical stage IA3 non-small cell lung cancer according to the International Association for the Study of Lung Cancer 9th edition tumor, node, metastasis classification; clinical T1cN0M0; tumor maximum diameter \\>2 cm and \\\u003C=3 cm on imaging evaluation.\n* Consolidation-to-tumor ratio (CTR) \\>0.5 and \\\u003C=1 on thin-section computed tomography.\n* Peripheral tumor judged by the investigator to be amenable to curative segmentectomy or lobectomy, with an anticipated ability to achieve the protocol-specified surgical margin.\n* Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1.\n* Preoperative pulmonary function adequate for surgery, with forced expiratory volume in 1 second \\>=60% predicted and single-breath diffusing capacity of the lung for carbon monoxide \\>=60% predicted, unless otherwise documented after multidisciplinary evaluation.\n* Willing to undergo intraoperative lymph node frozen-section biopsy to confirm node-negative status and understands that a positive frozen-section result will lead to conversion to lobectomy as standard treatment and exclusion from the primary efficacy analysis.\n* Able to understand the study and voluntarily sign written informed consent.\n\nExclusion Criteria:\n\n* Intraoperative lymph node frozen-section biopsy confirms N1 or N2 metastasis, or preoperative endobronchial ultrasound-guided biopsy or mediastinoscopy confirms N1, N2, or N3 metastasis, pleural dissemination, or distant metastasis. Patients with positive intraoperative frozen-section results will be converted to lobectomy plus systematic lymph node dissection as standard treatment and recorded as screen failures.\n* Multiple primary lung cancers or multiple pulmonary nodules requiring concurrent resection outside the protocol-defined scope that would affect assessment of the primary endpoint.\n* Prior ipsilateral lobectomy or segmentectomy, or severe pleural adhesions making the study procedure unevaluable.\n* Other active malignancy within 5 years, except cured low-risk tumors.\n* Severe cardiac, cerebral, hepatic, renal, or other disease that would preclude general anesthesia or curative lung cancer surgery.\n* Pregnant or breastfeeding women.\n* Any other condition that, in the investigator's opinion, makes the participant unsuitable for this study.","ALL","18 Years","80 Years",{"count":37,"type":38},100,"ESTIMATED","INTERVENTIONAL",[41],"NA","This is a single-center, prospective, single-arm, open-label clinical trial evaluating the efficacy and safety of septum-guided segmentectomy in patients with 2-3 cm clinical stage IA3 peripheral non-small cell lung cancer (NSCLC) with a consolidation-to-tumor ratio (CTR) greater than 0.5 and up to 1.0. All eligible participants will undergo planned septum-guided anatomical segmentectomy or combined segmentectomy after intraoperative frozen-section confirmation of node-negative (N0) lymph node status. The primary endpoint is 3-year recurrence-free survival (RFS).",[44],"Non-Small Cell Lung Cancer",[46,47,48],"segmentectomy","clinical stage IA3","peripheral NSCLC","NOT_YET_RECRUITING","2026-08-19",{"date":52,"type":53},"2026-08-21","ACTUAL",{"date":55,"type":38},"2026-08",{"date":57,"type":38},"2034-08",{"name":5,"class":6}]